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Conclusions This study demonstrated that the rapid pacing trough the
back-up left ventricle guidewire is equivalent to right ventricular pacing in
term of efficacy.
This method is safer due to the limitation of complications related to right
ventricular pacing lead placement. Finally, it simplify the procedure by making
it faster.
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Background TAVI offers an attractive option for patients with failed bio-
prosthesis and high operative risk (valve-in-valve concept). 
Purpose The objective of this study was to analyze outcomes of patients
with failed aortic bioprosthesis undergoing transcatheter aortic valve-in-valve
implantation.
Methods From January 2012 to January 2015, 15 patients with degenerated
aortic valve bioprosthesis underwent transcatheter aortic valve-in-valve
implantation in our institution. Mean patient age was 82±6 years. Mean
logistic Euroscore was 36±16% and mean STS score was 16±14%. The mean
follow-up was 260±316 days.
Results The failing bioprosthesis were Cryolife O’brien in 5 patients, Car-
pentier Edwards in 5 patients, Medtronic mosaic in 4 patients and Mitroflow
in 1 patient. Bioprosthesis mode of failure was stenosis (n=6), regurgitation
(n=5), or combined stenosis and regurgitation (n=4). The mean degenerative
time was 11.15±6.1 years.
Implanted devices included Medtronic CoreValve (n=6) and Edwards
SAPIEN (n=9). Successful implantation of a transcatheter aortic valve-in-
valve with the patient leaving the catheterization laboratory alive was
achieved in all patients. Adverse procedural outcomes included initial device
malposition in 3 cases requiring a second valve, retroperitoneal hematoma in
1 patient, permanent pacemaker in 1 patient, Stroke in 1 patient and acute
renal failure in 1 patient. The mean transvalvular gradient passed from
48.7±17.63 to 18.32±9.3mmHg in stenotic degenerated bioprosthesis. No
significant aortic regurgitation was observed post-implantation. During
hospitalization, 1 patient developed myocardial infarction. The medium in-
hospital stay was 13.4±7.7 days. During later follow-up, there was no death,
no myocardial infarction and no stroke or TIA. 2 patients were hospitalized
for heart failure.
Conclusion Transcatheter aortic valve-in-valve implantation seems to be
feasible and safe in both stenotic and regurgitant degenerative bioprosthesis. 
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Objectives It has been suggested that myocardial systolic deformation
parameters may be a more sensitive marker of left ventricular (LV) systolic
dysfunction than LV ejection fraction (LVEF). However, its prognostic value
in patients with aortic stenosis (AS) remains debated.
Methods In an ongoing prospective cohort of asymptomatic patients with
at least mild, pure, isolated AS, global longitudinal strain (GLS) was measured
at baseline using 2D speckle tracking imaging, and AS related events (occur-
rence of symptoms, congestive heart failure and sudden death) were prospec-
tively collected.
Results We prospectively enrolled 176 patients (mean age 72 years,
70% male). Mean aortic valve area was 1.25cm2 and mean gradient
28.8mmHg. Overall, 88 patients had mild AS, 50 patients moderate AS
and 38 patients severe AS. During a mean follow up period of 2.2 years,
38 events occurred. GLS was not correlated to pic velocity, mean gradient
or aortic valve area (AVA) (all p>0.05). In univariate analysis, neither in
the whole cohort (p=0.75), nor in the subgroup of moderate/severe AS,
GLS was predictive of future AS related events. Results were unchanged
after adjustment for AS hemodynamic severity (p=0.66 and p=0.82,
respectively).
Conclusions Our data suggest that longitudinal strain assessed by 2D
speckle tracking echocardiography, is not predictive of future symptomatic
status in asymptomatic patients with AS and preserved LVEF. Thus, this
index should not be recommended in daily practice, in order to select patients
who should undergo an early aortic valve replacement.
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Background Few data is available concerning the latest generation
Edwards SAPIEN 3- S3 in patients with severe aortic stenosis undergoing
transcatheter aortic valve implantation (TAVI).
Aims To evaluate periprocedural and 30-day clinical outcomes of TAVI
using the Edwards SAPIEN 3 prosthesis) via transiliofemoral approach.
Methods Between September 2014 and March 2015, consecutive high-risk
or non-operable patients with severe aortic stenosis had TAVI using Edwards
SAPIEN 3 prosthesis in Institut Mutualiste Montsouris. Valve Academic
Research Consortium endpoints were used.
Results Of 142 patients who underwent TAVI using Edwards SAPIEN
prosthesis, 66 were treated with SAPIEN 3 via transfemoral access (mean age
84±7.1 years; 70% female). About 65% and 48% of patients had, respectively,
severe peripheral artery diseases and calcified iliofemorale arteries. Multi-
detector computed tomography estimated an aortic annular diameter of
25,07±2mm. Mean logistic EuroSCORE was 15,8±10,8. The device success
rate was 98.5%. No failure of valve deployment had occurred and no patient
had more than mild paravalvular aortic regurgitation. Mean transaortic gra-
dient decreased from 46, 0±12,33mmHg to 8,2±3,37mmHg (p<0,001), at
30 days follow up, there were no myocardial infarction. The major bleedings
rate was 1.5%, and 6% of patients required transfusion. The major vascular
complications were 6%, mortality and stroke were of 3%, and the rate for a
new pacemaker was 10,6.
Conclusion In our study, TAVI with Edwards SAPIEN 3 was associated
with a high rate of device success and low rate of paravalvular aortic regurgi-
tations and major bleedings.
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